A psilocybin-assisted therapy company has gone public (as of 2020-09-22).

Judged as of 2020-09-22. True: on or before that date, a company whose core business is developing psilocybin-assisted therapy completed an IPO or a listing of its shares on a public stock exchange; a listing in the days just before the statement fits the claim. Mostly true: the listing took place, with a minor slip in a detail, such as psilocybin therapy being the company's lead programme rather than its only business. Mostly false: the only listed companies were psychedelic firms not focused on psilocybin-assisted therapy, or an IPO had only been filed or priced and not completed by that date. False: no psilocybin-assisted therapy company had gone public by 2020-09-22.

Set before the research began.

1. E1 COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares COMPASS Pathways plc (company press release, via its investor relations site) · 22 September 2020

   “The ADSs began trading on the Nasdaq Global Select Market on September 18, 2020 under the ticker symbol “CMPS.””

2. E2 COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares COMPASS Pathways plc (company press release, via its investor relations site) · 22 September 2020

   “We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.”

3. E3 Statement: MAPS Congratulates Compass Pathways on Initial Public Offering to Advance Psychedelic Therapies Multidisciplinary Association for Psychedelic Studies (MAPS) · 23 September 2020

   “today congratulated Compass Pathways on their initial public offering last Friday which has resulted a doubling of their stock price and $1.3 billion valuation.”

4. E4 2020's top 5 advancements in psychedelics Mugglehead · 30 December 2020

   “In September, Compass Pathways (Nasdaq: CMPS) debuted on Nasdaq, making it the first psychedelics firm to list on a major U.S. stock exchange.”

COMPASS Pathways announced on 2020-09-22 that its IPO had closed. It also said its ADSs began trading on the Nasdaq Global Select Market on September 18, 2020 (E1). The same release describes its core business as developing psilocybin therapy built around COMP360, its synthetic psilocybin formulation (E2). Independent sources confirm the IPO and Nasdaq debut (E3, E4). This is a completed listing by a psilocybin-therapy company in the days just before the claim date, which meets the criteria for true.